Soaring Eagle Acquisition Corp. Ginkgo Bioworks Highlight Will Begin Trading On NYSE As Of Friday, Sept. 17, 2021

The company announces the closing of its business combination with Soaring Eagle Acquisition Corp. Proceeds exceed $1.6 billion with major shareholders including ARK Investment Management LLC, Baillie Gifford, Putnam

The company announces the closing of its business combination with Soaring Eagle Acquisition Corp.
Proceeds exceed $1.6 billion with major shareholders including ARK Investment Management LLC, Baillie Gifford, Putnam Investments, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), and Franklin Advisers
New capital expected to fund the growth of Ginkgo’s leading cell programming platform
New board members include Dr. Arie Belldegrun, Executive Chairman and Co-Founder of Allogene Therapeutics, Reshma Kewalramani, Chief Executive Officer and President at Vertex, and Harry Sloan, Chairman and Chief Executive Officer of Soaring Eagle Acquisition Corp.

BOSTON, Sept. 17, 2021 /PRNewswire/ — Ginkgo Bioworks, Inc. (“Ginkgo”) and Soaring Eagle Acquisition Corp. (NASDAQ:SRNG) (“Soaring Eagle”), a special purpose acquisition company, today announced the closing of their previously announced business combination. The combined company is named Ginkgo Bioworks Holdings, Inc., and the combined company’s shares of Class A common stock and public warrants will begin trading today on the New York Stock Exchange under the ticker symbols “DNA” and “DNA.WS” respectively. The business combination was approved at a special meeting of Soaring Eagle stockholders on September 14, 2021.

Ginkgo launched in 2008 with the mission to make biology easier to engineer. Much like computer programming impacted every information-based industry through the ability to program the flow of data, cell programming has the potential to impact every physical goods industry through the ability to program the flow of atoms. Ginkgo’s platform leverages advanced robotic automation, proprietary software, and data analytics to continuously improve the technology (“Foundry”) as well as the knowledge and re-usable biological assets (“Codebase”) required to engineer biology. Today, companies across industries use Ginkgo’s cell programming platform to find more effective, environmentally friendly ways to create products including food ingredients, fragrances, cosmetics, medicines, and more. By enabling the design of organisms that can produce valuable biological products, Ginkgo helps accelerate the development of innovative, bio-based solutions to the world’s most pressing challenges.

“For nearly two decades, my co-founders and I have been on a mission to make programming cells as easy as programming computers,” said Jason Kelly, CEO and co-founder at Ginkgo. “Today marks an important milestone not only for the team at Ginkgo, but for synthetic biology as a whole, and I am thrilled to work with our team, partners and investors as we continue scaling our platform to solve even bigger problems with biology.”

In addition to Kelly, Ginkgo Bioworks will continue to be led by its founding team, including President/COO Reshma Shetty, Chief Technology Officer Barry Canton, Head of Strategy Austin Che, and the “godfather of synthetic biology,” DNA Hacker Tom Knight. Additionally, alongside Jason Kelly and Reshma Shetty, the board will welcome incoming directors Harry Sloan, Chairman and Chief Executive Officer of Soaring Eagle Acquisition Corp., Dr. Arie Belldegrun, MD, FACS, Executive Chairman and Co-Founder of Allogene Therapeutics, and Reshma Kewalramani, M.D., FASN, Chief Executive Officer and President at Vertex.

“Eagle Equity Partners has been exceptionally proud to sponsor Ginkgo’s entry into the public market. Jason, his co-founders and team are using the tools of engineering and computing to reprogram biology, and are committed to solving some of the world’s most pressing problems,” said Harry Sloan, Chairman and Chief Executive Officer of Soaring Eagle Acquisition Corp. “I look forward to supporting Ginkgo’s ongoing growth as a Board Member as they continue delivering on their great promise.”

The transaction provides total proceeds of over $1.6 billion and values Ginkgo at a $15 billion enterprise value. The largest investors include ARK Investment Management, Baillie Gifford, Putnam Investments, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), and Franklin Advisers. The proceeds are expected to fund the expansion of Ginkgo’s cell programming platform.

To celebrate the completion of the business combination, Ginkgo will ring the opening bell at the New York Stock Exchange (NYSE) at 9:30 am ET on September 17, 2021. A live stream of the event and replay can be accessed by visiting https://www.nyse.com/bell.

Total
0
Shares
Related Posts

Beta is now closed - Our Newswire is Live! Receive 50% off Your First Month!

X